​

Rapport Therapeutics (RAPP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RAPP Stock Forecast

Rapport Therapeutics (RAPP) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $51.00 and a low of $40.00. This represents a 70.13% increase from the last price of $26.45.

$15 $23 $31 $39 $47 $55 High: $51 Avg: $45 Low: $40 Last Closed Price: $26.45

RAPP Stock Rating

Rapport Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

RAPP Price Target Upside V Benchmarks

TypeNameUpside
StockRapport Therapeutics70.13%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$45.50$45.00
Last Closing Price$26.45$26.45$26.45
Upside/Downside-72.02%70.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2618---9
Dec, 2518---9
Nov, 2526---8
Oct, 2526---8
Sep, 2524---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2025Wells Fargo$51.00$29.6472.06%92.82%
Dec 09, 2025Douglas TsaoH.C. Wainwright$40.00$30.1632.63%51.23%
Sep 16, 2025Joon LeeTruist Financial$44.00$24.8577.06%66.35%
Jul 02, 2024Andrew TsaiJefferies$35.00$25.4437.58%32.33%
Jul 02, 2024Paul MatteisStifel Nicolaus$35.00$25.4437.58%32.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2026CitigroupMarket OutperformMarket Outperformhold
Dec 19, 2025Goldman SachsBuyBuyhold
Dec 09, 2025H.C. WainwrightBuyBuyhold
Sep 08, 2025H.C. WainwrightBuyBuyhold
Jul 02, 2024Cowen & Co.Buyinitialise
Jul 02, 2024JefferiesBuyinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported$-0.38-
Avg Forecast$-3.65$-3.37
High Forecast$-3.29$-3.12
Low Forecast$-3.87$-3.70
Surprise %-89.59%-

Revenue Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-650M $-530M $-410M $-290M $-170M $-50M Dec 24 Dec 25
Dec 24Dec 25
Reported$-78.31M-
Avg Forecast$-599.89M$-553.87M
High Forecast$-540.72M$-512.78M
Low Forecast$-636.05M$-608.11M
Surprise %-86.95%-

RAPP Forecast FAQ

Is Rapport Therapeutics stock a buy?

Rapport Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rapport Therapeutics is a favorable investment for most analysts.

What is Rapport Therapeutics's price target?

Rapport Therapeutics's price target, set by 4 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $40 at the low end to $51 at the high end, suggesting a potential 70.13% change from the previous closing price of $26.45.

How does Rapport Therapeutics stock forecast compare to its benchmarks?

Rapport Therapeutics's stock forecast shows a 70.13% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rapport Therapeutics over the past three months?

  • January 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Rapport Therapeutics’s EPS forecast?

Rapport Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.37, marking a 786.84% increase from the reported $-0.38 in 2024..

What is Rapport Therapeutics’s revenue forecast?

Rapport Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024.

What is Rapport Therapeutics’s net income forecast?

Rapport Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-554M, representing an 607.30% increase from the reported $-78.307M in 2024.